Rene Haas, the chief executive of Arm Holdings, the largest UK-headquartered technology firm, has asserted that artificial intelligence will discover a cure for cancer within our lifetimes, solving problems that remain beyond current human capability.
Haas, who stepped down from the board of pharmaceutical giant AstraZeneca in April, discussed his views during an interview with the BBC’s Big Boss Interview podcast. He acknowledged that while modeling how DNA markers are impacted by cancer is currently too complex for existing systems, he believes that as computers become more sophisticated and models more refined, the technology will eventually solve the issue.
The Cambridge-based company designs the microchips found in hundreds of billions of devices globally, including smartphones, cars, and smartwatches. Earlier this year, Arm’s surge in share price during the AI boom made it the most valuable UK-based company in history on a cash basis.
Haas also highlighted the growing demand for Arm’s power-efficient technology, noting that it now powers half of all AI data centers worldwide. He revealed that Meta has commissioned Arm to develop an AGI chip, generating over $2 billion in demand since the launch in March.
Despite the optimism, Haas pointed out that the rapid expansion of AI is being hindered by a shortage of chips required for data centers. He expressed skepticism about the feasibility of establishing chip manufacturing fabs in the UK, citing the high costs, specialized labor requirements, and resource needs involved.
On the topic of employment, Haas argued that fears of mass job losses due to AI are exaggerated. He predicted that humanoid robots would become common in service industries within five years, performing tasks such as cleaning and repairs, but maintained that new opportunities would outweigh any displacement.
Professor Chris Bakal, CEO of Sentinal4D and from the Institute of Cancer Research, London, offered a contrasting perspective on the path to medical breakthroughs. He emphasized that the critical factor is not the size of the computer, but the quality of the data used to train AI systems. Bakal noted that his team trains models on patient-generated data rather than internet-scraped information, which could significantly accelerate treatment development.
I just want to know: how much longer do we wait? Saying ‘within our lifetimes’ feels like enough time for some, but not others.
It is fascinating that a chip CEO is making such bold medical predictions. Are we letting Silicon Valley redefine medical timelines?
I am skeptical about the timeline. Curing cancer isn’t just a math problem; biology is messy and unpredictable in ways code isn’t.
But wait, Professor Bakal makes a good point. Garbage in, garbage out. Without high-quality patient data, even the best chips won’t help.
This is incredibly hopeful. If AI can model DNA complexities, maybe we truly are seeing the end of cancer as we know it.